statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024 NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May...

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression...

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression

NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression.
read more...

Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression NRx Pharmaceuticals (Nasdaq:NRXP...

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq...

NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement

NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of...

NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock

NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock PR Newswire RADNOR...

NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections

(NRXP) - Analyzing NRX Pharmaceuticals's Short Interest

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary...

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Watchers	12,792
52-Wk Low	$1.90
52-Wk High	$12.00

Volume	1.07M
52-Wk High	$12.00
52-Wk Low	$1.90

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.55	--	--	N/A
Q4'23	-$0.07	-$0.50	-614.29%	MISSED
Q3'23	-$0.11	-$0.07	36.36%	BEAT
Q2'23	-$0.13	-$0.12	10.00%	BEAT
Q1'23	-$0.14	-$0.16	-18.52%	MISSED

NRXP NRX Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals